CorEvitas® IBD Registry Launches Precision Medicine Program to Expand Treatment Insights & Advance Care
CorEvitas IBD Registry launches biospecimen study to expand treatment insights and advance patient care.
- CorEvitas IBD Registry launches biospecimen study to expand treatment insights and advance patient care.
- This biospecimen study will enable our industry partners to uncover even deeper clinical insights to optimize care for every patient in the future, no matter their phenotype," said Austin Read, Vice President, Precision Medicine at CorEvitas.
- CorEvitas' ability to collect rich longitudinal clinical data alongside biospecimens through its IBD Registry is quite timely, paving the way for the next wave of IBD therapeutics and diagnostics.
- The Precision Medicine business advances the molecular understanding of disease and prognostic tools by pairing registry data with select biospecimens and 'omics data.